Castle Biosciences (CSTL) Short-term Investments (2022 - 2026)

Castle Biosciences has reported Short-term Investments for 5 years, with the latest figure at $204.7 million in Q2 2026.

• Quarterly Short-term Investments rose 5.68% year-over-year to $204.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $204.7 million (up 5.68% YoY) and the FY2025 annual result came in at $182.8 million, up 5.39% from the prior year.
• Short-term Investments grew to $204.7 million in Q2 2026 per CSTL's latest filing, from $197.9 million in the prior quarter.
• Over five years, Short-term Investments peaked at $204.7 million in Q2 2026 and troughed at $117.2 million in Q1 2023.
• A 5-year average of $165.8 million and a median of $173.8 million in 2024 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments advanced 5.1% in 2023, then soared 34.31% in 2024.
• Over 5 years, Short-term Investments stood at $135.7 million in 2022, then increased by 6.32% to $144.3 million in 2023, then climbed by 20.22% to $173.4 million in 2024, then advanced by 5.39% to $182.8 million in 2025, then increased by 12.0% to $204.7 million in 2026.
• According to Business Quant data, Short-term Investments over the past three periods registered $204.7 million, $197.9 million, and $182.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.